Unleashing natural IL-18 activity using an anti-IL-18BP blocker antibody induces potent immune stimulation and anti-tumor effects


Compugen Ltd, Holon, Israel

Antibody induces potent immune stimulation and anti-tumor effects

CONCLUSION

• IL-18, upregulated in the TME, is inhibited by IL-18BP, which is induced by IFNγ in the TME. • Blocking IL-18BP in murine cancer models inhibited tumor growth. • Immune modulation following treatment with anti-IL-18BP Ab is restricted to the TME suggesting favorable therapeutic window, in contrast to recombinant therapeutic cytokines given systemically. • COM503, a human IgG4 high affinity anti-IL-18BP blocker Ab, released IL-18 to activate T and NK cells. • IND expected in 2024